free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Breckenridge Receives ANDA Approval for Asenapine Sublingual Tablets

americanpharmaceuticalreviewMarch 12, 2021

Tag: Breckenridge , Asenapine Sublingual Tablets , MSN

Breckenridge Pharmaceutical announced the U.S. Food and Drug Administration (FDA)has granted final approval of its Abbreviated New Drug Application (ANDA) for Asenapine Sublingual Tablets in 5mg strength (generic for Saphris?).

Breckenridge plans to launch this strength immediately. The Company previously launched the product's 2.5mg and 10mg strengths and will now market all three strengths. This product was developed in collaboration with MSN Laboratories Private Limited. According to industry sales data, Saphris? generated annual sales of $233 million during the twelve months ending December 2020.

Previous:NIAID grants $2.5m to 12 institutes for bacteriophage therapy research

Next:Pathios Receives Innovate UK Smart Grant

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service